GW&K Investment Management LLC Has $31.63 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

GW&K Investment Management LLC grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 19.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,375,407 shares of the biopharmaceutical company’s stock after buying an additional 225,238 shares during the quarter. GW&K Investment Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $31,634,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Aquatic Capital Management LLC boosted its stake in Ultragenyx Pharmaceutical by 79.1% in the 3rd quarter. Aquatic Capital Management LLC now owns 191,458 shares of the biopharmaceutical company’s stock valued at $5,759,000 after buying an additional 84,559 shares in the last quarter. Thornburg Investment Management Inc. acquired a new stake in Ultragenyx Pharmaceutical in the 3rd quarter valued at $2,083,000. Aberdeen Group plc boosted its stake in Ultragenyx Pharmaceutical by 94.3% in the 3rd quarter. Aberdeen Group plc now owns 973,656 shares of the biopharmaceutical company’s stock valued at $29,288,000 after buying an additional 472,600 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in Ultragenyx Pharmaceutical in the 4th quarter valued at $10,973,000. Finally, Rafferty Asset Management LLC boosted its stake in Ultragenyx Pharmaceutical by 93.0% in the 3rd quarter. Rafferty Asset Management LLC now owns 156,484 shares of the biopharmaceutical company’s stock valued at $4,707,000 after buying an additional 75,388 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 4,653 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 1st. The stock was sold at an average price of $23.77, for a total value of $110,601.81. Following the completion of the sale, the chief financial officer directly owned 105,689 shares of the company’s stock, valued at approximately $2,512,227.53. This trade represents a 4.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Shehnaaz Suliman sold 5,740 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, May 18th. The shares were sold at an average price of $25.12, for a total value of $144,188.80. Following the completion of the sale, the director directly owned 27,951 shares of the company’s stock, valued at $702,129.12. This trade represents a 17.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 20,103 shares of company stock valued at $478,186 over the last three months. Insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on RARE. HC Wainwright decreased their price target on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Morgan Stanley boosted their price target on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, April 16th. JPMorgan Chase & Co. dropped their price objective on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a report on Thursday, March 12th. Wells Fargo & Company raised their price objective on shares of Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, Guggenheim dropped their price objective on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating for the company in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $59.56.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE opened at $22.97 on Thursday. The stock has a fifty day moving average of $23.87 and a 200-day moving average of $25.21. The stock has a market capitalization of $2.26 billion, a P/E ratio of -3.76 and a beta of 0.37. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.29 and a 52 week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The firm had revenue of $136.00 million during the quarter, compared to analyst estimates of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The firm’s quarterly revenue was down 2.2% on a year-over-year basis. During the same period last year, the business posted ($1.57) earnings per share. Equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.57 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.